Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581860 · ClinicalTrials.gov registry record
Growth Hormone Resistance of Beta-cells
A clinical trial, sponsored by University of Missouri-Columbia.
- Not yet
- Registry status
- 10
- Enrollment target
NCT07581860 is a clinical trial that has not yet begun recruiting, run by University of Missouri-Columbia. The registered enrollment target is 10 participants.
The verdict
NCT07581860 has not yet begun recruiting, sponsored by University of Missouri-Columbia.
- NOT YET RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07581860
The ClinicalTrials.gov registry entry for NCT07581860 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07581860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07581860 about?
NCT07581860 is a clinical study titled "Growth Hormone Resistance of Beta-cells". The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to a...
What is the current status of trial NCT07581860?
This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-08-01. Estimated completion is 2030-09-01.
Who is sponsoring clinical trial NCT07581860?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.